Neurocrine Biosciences, Inc. Share Price

Equities

NBIX

US64125C1099

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 20:27:48 22/04/2024 BST 5-day change 1st Jan Change
132.6 USD +0.49% Intraday chart for Neurocrine Biosciences, Inc. +0.91% +0.89%
Sales 2024 * 2.21B 179B Sales 2025 * 2.52B 204B Capitalization 13.28B 1,075B
Net income 2024 * 490M 39.66B Net income 2025 * 664M 53.74B EV / Sales 2024 * 4.96 x
Net cash position 2024 * 2.3B 186B Net cash position 2025 * 3.04B 246B EV / Sales 2025 * 4.06 x
P/E ratio 2024 *
28 x
P/E ratio 2025 *
20.8 x
Employees 1,400
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.73%
More Fundamentals * Assessed data
Dynamic Chart
Nxera Pharma's Neuro Drug NBI-1117568 Passed Preclinical Toxicity Test MT
Neurocrine Biosciences, Sentia Medical Sciences Extend Partnership on Prospective Drug Development MT
Sentia Medical Sciences Inc. and Neurocrine Biosciences, Inc. Extend Research Collaboration to Discover Novel CRF Peptides CI
Morgan Stanley Lifts Price Target on Neurocrine Biosciences to $160 From $150, Sees Upside to Shares Ahead of Mid-Stage Readouts; Overweight Kept MT
Neurocrine Biosciences Doses First Patient in Phase 2 Depressive Disorder Study MT
Neurocrine Biosciences, Inc. Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder CI
Neurocrine Biosciences Starts Phase 1 Trial of Investigational Neuropsychiatric Drug MT
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults CI
JPMorgan Adjusts Price Target on Neurocrine Biosciences to $158 From $148, Maintains Overweight Rating MT
Transcript : Neurocrine Biosciences, Inc. Presents at Stifel Virtual 2024 CNS Day, Mar-19-2024 02:00 PM
Transcript : Neurocrine Biosciences, Inc. Presents at UBS Virtual CNS Day 2024, Mar-18-2024 12:00 PM
Neurocrine Biosciences Insider Sold Shares Worth $5,576,710, According to a Recent SEC Filing MT
Neurocrine Biosciences Insider Sold Shares Worth $420,419, According to a Recent SEC Filing MT
Transcript : Neurocrine Biosciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 10:15 AM
Oppenheimer Adjusts Neurocrine Biosciences Price Target to $200 From $170, Maintains Outperform Rating MT
More news
1 day+0.54%
1 week+0.91%
Current month-3.61%
1 month-6.01%
3 months-4.91%
6 months+23.19%
Current year+0.89%
More quotes
1 week
130.13
Extreme 130.13
135.18
1 month
130.13
Extreme 130.13
142.31
Current year
128.00
Extreme 128
148.37
1 year
89.04
Extreme 89.04
148.37
3 years
71.88
Extreme 71.875
148.37
5 years
71.85
Extreme 71.85
148.37
10 years
12.63
Extreme 12.6325
148.37
More quotes
Managers TitleAgeSince
Founder 66 31/12/91
Director of Finance/CFO 44 31/10/17
Chief Tech/Sci/R&D Officer 60 29/11/21
Members of the board TitleAgeSince
Director/Board Member 75 31/03/99
Director/Board Member 72 30/09/15
Founder 66 31/12/91
More insiders
Date Price Change Volume
22/04/24 132.9 +0.71% 314 836
19/04/24 132 -0.41% 556,303
18/04/24 132.5 -0.52% 586,541
17/04/24 133.2 +0.18% 571,093
16/04/24 133 +0.95% 1,033,219

Delayed Quote Nasdaq, April 22, 2024 at 08:11 pm

More quotes
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
132 USD
Average target price
152.5 USD
Spread / Average Target
+15.52%
Consensus